Literature DB >> 1462897

Adenosine is an endogenous protectant against stunning during repetitive ischemic episodes in the heart.

F T Bunch1, J Thornton, M V Cohen, J M Downey.   

Abstract

To investigate whether adenosine receptor blockade alters the response to serial coronary occlusions in the rabbit heart, we measured changes in segment length with ultrasonic dimension gauges placed in the field of a coronary branch. The coronary branch was subjected to four 5-minute occlusions, each separated by 10 minutes of reperfusion. In control hearts, the percentage of segment shortening fell from 15.7% to 9.3% after release of the first occlusion with no further deterioration after each of the subsequent three occlusions. In hearts in which adenosine receptors were blocked with PD 115,199, a potent blocker of both A1 and A2 receptors, segment shortening again recovered to about two thirds of the preischemic value during the reperfusion period after the first occlusion. Each subsequent occlusion, however, resulted in a further deterioration of function to the extent that shortening was less than 20% of the preischemic value during reperfusion after the fourth occlusion. Therefore the first occlusion of a series of four occlusions, while mildly stunning the heart, also preconditions the myocardium against further stunning by subsequent occlusions. Because that protection was when adenosine receptors were blocked, adenosine must play an important role in the mediation of this protective effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1462897     DOI: 10.1016/0002-8703(92)90055-z

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

Review 1.  The early and late phases of preconditioning against myocardial stunning and the essential role of oxyradicals in the late phase: an overview.

Authors:  R Bolli
Journal:  Basic Res Cardiol       Date:  1996 Jan-Feb       Impact factor: 17.165

2.  Studies of the nucleoside transporter inhibitor, draflazine, in the human myocardium.

Authors:  M Böhm; C Weinhold; R H Schwinger; J Müller-Ehmsen; D Böhm; H Reichenspurner; B Reichart; E Erdmann
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

3.  Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs.

Authors:  T B McClanahan; D P Ignasiak; B J Martin; T E Mertz; K P Gallagher
Journal:  Basic Res Cardiol       Date:  1995 Mar-Apr       Impact factor: 17.165

4.  Late preconditioning against myocardial stunning. An endogenous protective mechanism that confers resistance to postischemic dysfunction 24 h after brief ischemia in conscious pigs.

Authors:  J Z Sun; X L Tang; A A Knowlton; S W Park; Y Qiu; R Bolli
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

Review 5.  Mechanisms of pain in angina pectoris--a critical review of the adenosine hypothesis.

Authors:  C Sylvén
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

6.  Recurrent ischemia in the canine heart causes recurrent bursts of free radical production that have a cumulative effect on contractile function. A pathophysiological basis for chronic myocardial "stunning".

Authors:  R Bolli; M Zughaib; X Y Li; X L Tang; J Z Sun; J F Triana; P B McCay
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.